Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asahi Builds Medical Media Plant In Korea To Meet Demand From China, India

This article was originally published in PharmAsia News

Executive Summary

Asahi Kasei Chemicals Corp. March 6 announced a plan to build a plant to manufacture pharmaceutical media acetonitrile in Ulsan, Korea.

Asahi Kasei Chemicals Corp. March 6 announced a plan to build a plant to manufacture pharmaceutical media acetonitrile in Ulsan, Korea. The plant is scheduled to start operations in January 2014, producing 11,000 tons each year. Although Asahi has a domestic production site in Kawasaki with a capability of 14,000 tons, the company, affected by last year’s earthquake, hopes the new facility will diversify risks and ensure a stable supply. In addition to supplying the Korean market, Asahi will ship products to China and India to meet local demands. Asahi Kasei is one of the largest acetonitrile makers in Asia. (Click here for more – Japanese language)

“Asahi Kasei Builds New Plant In Korea And Starts Operation January 2014”Fuji Sankei Business News (3/7/2012)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel